Clinical development of the GnRH agonist leuprolide acetate depot
Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive trea...
Saved in:
Main Author: | |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_d7d62ce674c943f8b7b81c9f9dc295c6 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Kristof Chwalisz, M.D., Ph.D. |e author |
245 | 0 | 0 | |a Clinical development of the GnRH agonist leuprolide acetate depot |
260 | |b Elsevier, |c 2023-06-01T00:00:00Z. | ||
500 | |a 2666-3341 | ||
500 | |a 10.1016/j.xfre.2022.11.011 | ||
520 | |a Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection. | ||
546 | |a EN | ||
690 | |a Diseases of the genitourinary system. Urology | ||
690 | |a RC870-923 | ||
690 | |a Gynecology and obstetrics | ||
690 | |a RG1-991 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n F&S Reports, Vol 4, Iss 2, Pp 33-39 (2023) | |
787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2666334122001222 | |
787 | 0 | |n https://doaj.org/toc/2666-3341 | |
856 | 4 | 1 | |u https://doaj.org/article/d7d62ce674c943f8b7b81c9f9dc295c6 |z Connect to this object online. |